tetano
Editor, Senior Moderator
Sci Rep
. 2021 Mar 23;11(1):6614.
doi: 10.1038/s41598-021-86035-2.
Accurate SARS-CoV-2 seroprevalence surveys require robust multi-antigen assays
Christos Fotis[SUP] #[/SUP][SUP] 1 [/SUP], Nikolaos Meimetis[SUP] #[/SUP][SUP] 1 [/SUP], Nikos Tsolakos[SUP] #[/SUP][SUP] 2 [/SUP], Marianna Politou[SUP] #[/SUP][SUP] 3 [/SUP], Karolina Akinosoglou[SUP] #[/SUP][SUP] 4 [/SUP], Vaia Pliaka[SUP] 2 [/SUP], Angeliki Minia[SUP] 2 [/SUP], Evangelos Terpos[SUP] 3 [/SUP], Ioannis P Trougakos[SUP] 5 [/SUP], Andreas Mentis[SUP] 6 [/SUP], Markos Marangos[SUP] 4 [/SUP], George Panayiotakopoulos[SUP] 7 8 [/SUP], Meletios A Dimopoulos[SUP] 3 [/SUP], Charalampos Gogos[SUP] 4 [/SUP], Alexandros Spyridonidis[SUP] 9 [/SUP], Leonidas G Alexopoulos[SUP] 10 11 [/SUP]
Affiliations
Abstract
There is a plethora of severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) serological tests based either on nucleocapsid phosphoprotein (N), S1-subunit of spike glycoprotein (S1) or receptor binding domain (RBD). Although these single-antigen based tests demonstrate high clinical performance, there is growing evidence regarding their limitations in epidemiological serosurveys. To address this, we developed a Luminex-based multiplex immunoassay that detects total antibodies (IgG/IgM/IgA) against the N, S1 and RBD antigens and used it to compare antibody responses in 1225 blood donors across Greece. Seroprevalence based on single-antigen readouts was strongly influenced by both the antigen type and cut-off value and ranged widely [0.8% (95% CI 0.4-1.5%)-7.5% (95% CI 6.0-8.9%)]. A multi-antigen approach requiring partial agreement between RBD and N or S1 readouts (RBD&N|S1 rule) was less affected by cut-off selection, resulting in robust seroprevalence estimation [0.6% (95% CI 0.3-1.1%)-1.2% (95% CI 0.7-2.0%)] and accurate identification of seroconverted individuals.
. 2021 Mar 23;11(1):6614.
doi: 10.1038/s41598-021-86035-2.
Accurate SARS-CoV-2 seroprevalence surveys require robust multi-antigen assays
Christos Fotis[SUP] #[/SUP][SUP] 1 [/SUP], Nikolaos Meimetis[SUP] #[/SUP][SUP] 1 [/SUP], Nikos Tsolakos[SUP] #[/SUP][SUP] 2 [/SUP], Marianna Politou[SUP] #[/SUP][SUP] 3 [/SUP], Karolina Akinosoglou[SUP] #[/SUP][SUP] 4 [/SUP], Vaia Pliaka[SUP] 2 [/SUP], Angeliki Minia[SUP] 2 [/SUP], Evangelos Terpos[SUP] 3 [/SUP], Ioannis P Trougakos[SUP] 5 [/SUP], Andreas Mentis[SUP] 6 [/SUP], Markos Marangos[SUP] 4 [/SUP], George Panayiotakopoulos[SUP] 7 8 [/SUP], Meletios A Dimopoulos[SUP] 3 [/SUP], Charalampos Gogos[SUP] 4 [/SUP], Alexandros Spyridonidis[SUP] 9 [/SUP], Leonidas G Alexopoulos[SUP] 10 11 [/SUP]
Affiliations
- PMID: 33758278
- DOI: 10.1038/s41598-021-86035-2
Abstract
There is a plethora of severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) serological tests based either on nucleocapsid phosphoprotein (N), S1-subunit of spike glycoprotein (S1) or receptor binding domain (RBD). Although these single-antigen based tests demonstrate high clinical performance, there is growing evidence regarding their limitations in epidemiological serosurveys. To address this, we developed a Luminex-based multiplex immunoassay that detects total antibodies (IgG/IgM/IgA) against the N, S1 and RBD antigens and used it to compare antibody responses in 1225 blood donors across Greece. Seroprevalence based on single-antigen readouts was strongly influenced by both the antigen type and cut-off value and ranged widely [0.8% (95% CI 0.4-1.5%)-7.5% (95% CI 6.0-8.9%)]. A multi-antigen approach requiring partial agreement between RBD and N or S1 readouts (RBD&N|S1 rule) was less affected by cut-off selection, resulting in robust seroprevalence estimation [0.6% (95% CI 0.3-1.1%)-1.2% (95% CI 0.7-2.0%)] and accurate identification of seroconverted individuals.